Brigatinib - ARIAD Pharmaceuticals

Drug Profile

Brigatinib - ARIAD Pharmaceuticals

Alternative Names: ALUNBRIG; AP-26113

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antineoplastics; Diamines; Piperazines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Cytochrome P-450 enzyme system stimulants; Epidermal growth factor receptor antagonists; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Lymphoma; Neuroblastoma

Most Recent Events

  • 25 Sep 2018 ARIAD Pharmaceuticals completes enrolment in its phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease) in Taiwan, Switzerland, Singapore, Luxembourg, Hong Kong, France, Denmark, Sweden, Finland, Germany, United Kingdom, Norway, Spain, Netherlands, South Korea, Italy, Canada, Australia, Austria (PO) (NCT02737501)
  • 25 Sep 2018 Updated efficacy data from the phase III ALTA-1L trial in Non-small cell lung cancer released by Takeda
  • 20 Sep 2018 Committee for Medicinal Products for Human Use recommends approval of brigatinib for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top